Diagnostics
Cardio Diagnostics Leverages AI, Genetics and Epigenetics to Transform Cardiovascular Risk Detection
Cardio Diagnostics Holdings uses AI and epigenetic biomarkers to enhance cardiovascular disease prevention and management, offering a suite of personalized solutions.
VolitionRx Expands Patent Portfolio with Ebola Triage Application
VolitionRx has filed a patent for using its Nu.Q technology to triage and monitor potential Ebola patients, aiming to provide low-cost bedside testing in resource-limited outbreak zones.
Scientists Make Progress on Blood Test for Early Lung Cancer Detection
Researchers are developing a blood test that could identify individuals at high risk for lung cancer, addressing the limitations of current screening focused solely on smoking history.
Cardio Diagnostics Leverages AI to Address Preventable Cardiovascular Disease
Cardio Diagnostics Holdings Inc. offers AI-powered solutions for early detection and prevention of cardiovascular disease, addressing the urgent need for more effective risk identification tools.
MindBio Therapeutics Uses AI Voice Analysis to Detect Intoxication in Real Time, Targeting Multibillion-Dollar Healthcare Market
MindBio Therapeutics is developing an AI-powered platform that analyzes brief voice recordings to detect drug and alcohol impairment, addressing a critical gap in current detection methods and tapping into a growing market for noninvasive, real-time diagnostics.
AI Voice Analysis for Intoxication Detection Gains Traction: MindBio Therapeutics Featured in BioMedWire Editorial
MindBio Therapeutics Corp. is highlighted in a BioMedWire editorial for its AI-driven voice analysis platform that detects real-time impairment, with implications for law enforcement, workplace safety, and healthcare.
Aclarion Adds First Private Practice Site in Los Angeles to CLARITY Trial
Aclarion announced the addition of Lanman Spinal Neurosurgery in Beverly Hills to its CLARITY trial, expanding enrollment beyond academic centers and highlighting growing interest in Nociscan for precise chronic low back pain diagnosis.
MindBio Therapeutics Adds AI-Powered Fatigue Detection to Voice-Based Diagnostics Platform
MindBio Therapeutics expands its AI voice diagnostics platform with fatigue recognition technology for high-risk industries, with commercial testing expected in late Q2 2026.
MindBio Therapeutics Advances AI Voice-Based Intoxication Detection Amid Growing Real-Time Diagnostics Market
MindBio Therapeutics is developing an AI-driven voice analysis platform to detect drug and alcohol intoxication in real time, targeting workplace safety, healthcare, and public safety markets as traditional testing methods face limitations.
AI and Multi-Omics Converge: Cardio Diagnostics Targets Earlier, More Precise Cardiac Insights
Cardio Diagnostics Holdings is leveraging artificial intelligence and multi-omic biomarkers to improve early detection and personalized treatment of cardiovascular disease, addressing a critical gap in traditional risk assessment.
Cardio Diagnostics Harnesses AI and Biomarkers to Combat Heart Disease Burden
Cardio Diagnostics Holdings is advancing early detection of cardiovascular disease using an AI-powered platform that analyzes epigenetic and genetic biomarkers from a simple blood sample, addressing the leading cause of death in the U.S.
VolitionRx Achieves Technical Milestone in Sepsis Detection with Finger-Prick Prototype
VolitionRx announced a prototype that can detect nucleosomes in capillary blood from sepsis patients, potentially enabling point-of-care testing and expanding access in regions with limited lab infrastructure.
MindBio Therapeutics Develops AI-Powered Voice Analysis for Non-Invasive Drug and Alcohol Detection
MindBio Therapeutics is launching an AI-driven voice analysis technology to detect impairment, targeting a growing $4.2 billion testing market and offering a less invasive alternative to traditional methods.
Cardio Diagnostics Leverages AI and Multi-Omic Biomarkers to Combat Cardiovascular Disease
Cardio Diagnostics Holdings is advancing AI-driven blood tests for earlier, more personalized detection and management of cardiovascular disease, addressing the leading cause of death in the U.S.
Cardio Diagnostics Leverages AI and Genomics to Revolutionize Cardiovascular Disease Detection
Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing AI-powered solutions using simple blood tests to detect and manage cardiovascular disease, addressing the leading cause of death in the US.
Cardio Diagnostics' AI Platform Aims to Transform Cardiovascular Risk Assessment
Cardio Diagnostics Holdings uses artificial intelligence and multi-omic data from a simple blood draw to provide personalized cardiovascular risk assessments, potentially shifting heart health diagnostics from population-based models to precise, individualized insights.
Novel Urine Test May Predict Bladder Cancer Treatment Response
Researchers have developed a urine test that detects tumor DNA to predict residual bladder cancer after surgery and assess immunotherapy effectiveness.
Cardio Diagnostics Holdings Gains Attention for AI-Driven Cardiovascular Platform
Cardio Diagnostics Holdings is highlighted as a company to watch due to its AI-powered approach to cardiovascular disease prevention, detection, and management, integrating epigenetics and genetics for personalized insights.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Cardio Diagnostics Holdings Leverages AI and Epigenetics for Advanced Cardiovascular Disease Management
Cardio Diagnostics Holdings is advancing cardiovascular disease prevention and detection through an AI-driven platform that integrates genetics and epigenetics to provide personalized insights.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
Utah Governor and BioUtah Recognize Co-Diagnostics Following Saudi Arabia Joint Venture
Co-Diagnostics' expansion into Saudi Arabia through a new joint venture demonstrates Utah's growing influence in global life sciences and represents significant international market penetration for local diagnostic technology.
Combined Biomarker Analysis Reveals Triple Heart Attack Risk in High-Risk Individuals
A new study shows that analyzing three specific biomarkers together can identify individuals with nearly triple the risk of heart attack, potentially enabling earlier intervention and personalized prevention strategies.
FDA Clears First 4-in-1 Home Test for RSV, Flu, and COVID Detection
ACON Laboratories has received FDA clearance for the first over-the-counter home test that simultaneously detects RSV, influenza A, influenza B, and COVID-19, representing a significant advancement in consumer respiratory health monitoring.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
New Melanoma Test Shows Three-Fold Improvement in Predicting Lymph Node Metastasis Risk
The Merlin CP-GEP test accurately stratifies melanoma patients by sentinel node metastasis risk, potentially reducing unnecessary surgical procedures through improved personalized care.
AXIM Biotechnologies Secures Exclusive South Korean Distribution for TearScan Diagnostic Tests
AXIM Biotechnologies has partnered with VisionPlus Corp. to exclusively distribute its TearScan diagnostic tests in South Korea, expanding access to advanced ocular diagnostics in a market experiencing rising dry eye disease cases.
FDA Approves One-Minute HIV Self-Test in Major Public Health Advancement
The FDA's approval of bioLytical's INSTI® HIV Self Test, which provides results in 60 seconds, represents a significant step toward reducing undiagnosed HIV cases and supporting national goals to end the HIV epidemic by making testing more accessible and private.
AXIM Biotechnologies Partners with JK Medical to Expand Ocular Diagnostic Access Across Latin America
AXIM Biotechnologies has entered an exclusive licensing agreement with JK Medical to distribute its TearScan® diagnostic tests across seven Latin American countries, addressing critical unmet needs in dry eye disease diagnosis through rapid point-of-care testing.
VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services
VolitionRx has entered a co-marketing agreement with Hologic to promote its Nu.Q® Discover epigenetic profiling service, expanding access to pharmaceutical and academic researchers in a market valued at $200 million annually.